A prospective trial of midwest breast cancer patients: A p53 gene mutation is the most important predictor of adverse outcome

Hagen Blaszyk, Arndt Hartmann, Julie M Cunningham, Daniel J Schaid, Lester E. Wold, John S. Kovach, Steve S. Sommer

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow-up) with a rigorous mutation detection methodology. The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence (p = 0.0032) and death (p = 0.0001), and was associated with poor response to both adjuvant (p = 0.0001) and palliative (p = 0.006) therapy. Analysis of the p53 gene with appropriate mutation detection methodology markedly improves the prediction of early recurrence, treatment failure, and death in breast cancer patients. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)32-38
Number of pages7
JournalInternational Journal of Cancer
Volume89
Issue number1
DOIs
StatePublished - Jan 20 2000

Fingerprint

p53 Genes
Breast Neoplasms
Mutation
Recurrence
Treatment Failure
Retrospective Studies
Therapeutics
Growth
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A prospective trial of midwest breast cancer patients : A p53 gene mutation is the most important predictor of adverse outcome. / Blaszyk, Hagen; Hartmann, Arndt; Cunningham, Julie M; Schaid, Daniel J; Wold, Lester E.; Kovach, John S.; Sommer, Steve S.

In: International Journal of Cancer, Vol. 89, No. 1, 20.01.2000, p. 32-38.

Research output: Contribution to journalArticle

@article{1a6e6cb4b62a4e0c8fc6a7b05d6ff8f1,
title = "A prospective trial of midwest breast cancer patients: A p53 gene mutation is the most important predictor of adverse outcome",
abstract = "Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow-up) with a rigorous mutation detection methodology. The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence (p = 0.0032) and death (p = 0.0001), and was associated with poor response to both adjuvant (p = 0.0001) and palliative (p = 0.006) therapy. Analysis of the p53 gene with appropriate mutation detection methodology markedly improves the prediction of early recurrence, treatment failure, and death in breast cancer patients. (C) 2000 Wiley-Liss, Inc.",
author = "Hagen Blaszyk and Arndt Hartmann and Cunningham, {Julie M} and Schaid, {Daniel J} and Wold, {Lester E.} and Kovach, {John S.} and Sommer, {Steve S.}",
year = "2000",
month = "1",
day = "20",
doi = "10.1002/(SICI)1097-0215(20000120)89:1<32::AID-IJC6>3.0.CO;2-G",
language = "English (US)",
volume = "89",
pages = "32--38",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - A prospective trial of midwest breast cancer patients

T2 - A p53 gene mutation is the most important predictor of adverse outcome

AU - Blaszyk, Hagen

AU - Hartmann, Arndt

AU - Cunningham, Julie M

AU - Schaid, Daniel J

AU - Wold, Lester E.

AU - Kovach, John S.

AU - Sommer, Steve S.

PY - 2000/1/20

Y1 - 2000/1/20

N2 - Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow-up) with a rigorous mutation detection methodology. The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence (p = 0.0032) and death (p = 0.0001), and was associated with poor response to both adjuvant (p = 0.0001) and palliative (p = 0.006) therapy. Analysis of the p53 gene with appropriate mutation detection methodology markedly improves the prediction of early recurrence, treatment failure, and death in breast cancer patients. (C) 2000 Wiley-Liss, Inc.

AB - Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow-up) with a rigorous mutation detection methodology. The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence (p = 0.0032) and death (p = 0.0001), and was associated with poor response to both adjuvant (p = 0.0001) and palliative (p = 0.006) therapy. Analysis of the p53 gene with appropriate mutation detection methodology markedly improves the prediction of early recurrence, treatment failure, and death in breast cancer patients. (C) 2000 Wiley-Liss, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034688185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034688185&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(20000120)89:1<32::AID-IJC6>3.0.CO;2-G

DO - 10.1002/(SICI)1097-0215(20000120)89:1<32::AID-IJC6>3.0.CO;2-G

M3 - Article

C2 - 10719728

AN - SCOPUS:0034688185

VL - 89

SP - 32

EP - 38

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -